|
|
Volumn 22, Issue 7, 2014, Pages 2280-2293
|
|
Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H- pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus
a
|
|
Author keywords
Glucokinase activator (GKA); Type 2 diabetes mellitus (T2DM)
|
|
Indexed keywords
3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL) N (4 MORPHOLIN 4 YLMETHYLTHIAZOL 2 YL)BENZAMIDE;
3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL) N (4 PIPERAZIN 1 YLMETHYLTHIAZOL 2 YL)BENZAMIDE;
3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL) N (4 PROP 2 YNYLAMINOMETHYLTHIAZOL 2 YL)BENZAMIDE;
3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL) N (4 PROPYLAMINOMETHYLTHIAZOL 2 YL)BENZAMIDE;
3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL) N THIAZOL 2 YL BENZAMIDE;
3 (4 METHANESULFONYLPHENOXY) N (1 METHYL 1H PYRAZOL 3 YL) 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
3 (4 METHANESULFONYLPHENOXY) N [1 (2 METHOXYETHOXYMETHYL) 1H PYRAZOL 3 YL] 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
3 (4 METHANESULFONYLPHENOXY) N [4 (4 METHYLPIPERAZIN 1 YLMETHYL)THIAZOL 2 YL] 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
3 (4 METHANESULFONYLPHENOXY) N [4 [(2 METHOXY 1 METHYLETHYLAMINO)METHYL]THIAZOL 2 YL] 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
3 (4 METHANESULFONYLPHENOXY) N [4 [[(2 METHOXYETHYL)METHYL AMINO]METHYL]THIAZOL 2 YL] 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
ANTIDIABETIC AGENT;
BENZAMIDE DERIVATIVE;
GKA 50;
GLIMEPIRIDE;
GLUCOKINASE;
GLUCOSE;
METFORMIN;
N (1 ETHOXYMETHYL 1H PYRAZOL 3 YL) 3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
N (4 CYCLOPROPYLCARBAMOYLMETHYLTHIAZOL 2 YL) 3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDINE 2 YL)BENZAMIDE;
N (4 DIETHYLAMINOMETHYLTHIAZOL 2 YL) 3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
N (4 ETHYLCARBAMOYLMETHYLTHIAZOL 2 YL) 3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDINE 2 YL)BENZAMIDE;
N (5 FLUOROTHIAZOL 2 YL) 3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
N [4 (ISOPROPYLAMINOMETHYL)THIAZOL 2 YL] 3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
N [4 [(2,2 DIMETHOXYETHYLAMINO)METHYL]THIAZOL 2 YL] 3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
N [4 [[BIS(2 METHOXY ETHYL)AMINO]METHYL]THIAZOL 2 YL] 3 (4 METHANESULFONYLPHENOXY) 5 (3 METHYLPYRIDIN 2 YL)BENZAMIDE;
SITAGLIPTIN;
UNCLASSIFIED DRUG;
3-(4-METHANESULFONYLPHENOXY)-N-(1-(2-METHOXYETHOXYMETHYL)-1H-PYRAZOL-3-YL)-5-(3-METHYLPYRIDIN-2-YL)BENZAMIDE;
ENZYME ACTIVATOR;
GLUCOSE BLOOD LEVEL;
INSULIN;
SULFONE;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
ANTIDIABETIC ACTIVITY;
AREA UNDER THE CURVE;
ARTICLE;
BEAGLE;
C57BL 6 MOUSE;
CONTROLLED STUDY;
DISTRIBUTION VOLUME;
DRUG BIOAVAILABILITY;
DRUG CLEARANCE;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG METABOLISM;
DRUG SOLUBILITY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
DRUG TOXICITY;
FEMALE;
GLUCOSE BLOOD LEVEL;
GLUCOSE TRANSPORT;
HUMAN;
INSULIN RELEASE;
LIVER CELL;
LIVER MICROSOME;
LIVER TOXICITY;
MALE;
MAXIMUM PLASMA CONCENTRATION;
MEAN RESIDENCE TIME;
MOLECULAR DOCKING;
MOUSE;
MUTAGENICITY;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
ORAL GLUCOSE TOLERANCE TEST;
PANCREAS ISLET;
RAT;
REPRODUCTIVE TOXICITY;
SINGLE DRUG DOSE;
STRUCTURE ACTIVITY RELATION;
TIME TO MAXIMUM PLASMA CONCENTRATION;
TOXICOKINETICS;
ANIMAL;
C57BL MOUSE;
CELL LINE;
CHEMICAL STRUCTURE;
CHEMISTRY;
DIABETES MELLITUS, EXPERIMENTAL;
DIABETES MELLITUS, TYPE 2;
DOG;
DOSE RESPONSE;
DRUG DEVELOPMENT;
DRUG EFFECTS;
ENZYMOLOGY;
INSTITUTE FOR CANCER RESEARCH MOUSE;
METABOLISM;
MOUSE MUTANT;
SPRAGUE DAWLEY RAT;
SYNTHESIS;
MUS;
RATTUS;
ANIMALS;
BENZAMIDES;
BLOOD GLUCOSE;
CELL LINE;
DIABETES MELLITUS, EXPERIMENTAL;
DIABETES MELLITUS, TYPE 2;
DOGS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG DISCOVERY;
ENZYME ACTIVATORS;
FEMALE;
GLUCOKINASE;
HEPATOCYTES;
HUMANS;
HYPOGLYCEMIC AGENTS;
INSULIN;
ISLETS OF LANGERHANS;
MALE;
MICE;
MICE, INBRED C57BL;
MICE, INBRED ICR;
MICE, OBESE;
MODELS, MOLECULAR;
MOLECULAR STRUCTURE;
RATS;
RATS, SPRAGUE-DAWLEY;
STRUCTURE-ACTIVITY RELATIONSHIP;
SULFONES;
|
|
EID: 84897457590
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2014.02.009 Document Type: Article |
|
Times cited : (29)
|
|
References (41)
|
